Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2026 | $18.00 | Outperform → In-line | Evercore ISI |
| 12/11/2025 | $20.00 | Neutral → Buy | Citigroup |
| 12/2/2025 | $21.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/1/2025 | $16.00 | Neutral | Goldman |
| 5/2/2025 | $20.00 → $15.00 | Buy | H.C. Wainwright |
| 3/28/2025 | $24.00 → $15.00 | Overweight → Equal Weight | Wells Fargo |
| 12/11/2024 | $24.00 → $22.00 | Buy → Neutral | Citigroup |
| 12/2/2024 | $19.00 | Overweight → Equal-Weight | Morgan Stanley |
Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00
Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00
Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
DEF 14A - Bausch & Lomb Corp (0001860742) (Filer)
10-K - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
Drawing on more than two decades of scientific evidence, a comprehensive review synthesizes more than 20 human studies highlighting the potential role of certain B vitamins in supporting eye health to help protect against age-related macular degeneration (AMD) PreserVision AREDS3™ eye vitamins combine a unique B-vitamin complex with clinically proven AREDS2 nutrients, intended to expand eye-health support to a broad range of people* PreserVision AREDS3 eye vitamins enhanced with B vitamins are now available in the U.S. and are expected to be at most major retailers by June 2026 The strength of this body of evidence has initiated planning for a long-term clinical trial to evaluate
The Broader Perspective framework sets direction for long-term environmental and social impact Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of its 2025 Sustainability Impact Report, outlining progress against its environmental, social and governance priorities and introducing The Broader Perspective, the company's sustainability framework designed to guide future action and accountability. Anchored in the belief that seeing the full picture leads to smarter decisions and greater impact, the new framework highlights how Bausch + Lomb is working across its global operations
Bausch + Lomb's ONE by ONE Recycling program helps prevent small, often overlooked eye health materials from entering landfills and waterways Program highlights the ongoing efforts of eye care practices, patients and consumers in collecting and recycling these used materials The initiative supports the company's long-standing environmental commitments and contributes to its FEWW sustainability metrics – fuel, energy, water and waste Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For Against Broker Non-Votes Nathalie Bernier 337,617,248 1,924,336 8,383,437 Gary Hu 337,591,706 1,949,878 8,383,437 Brett Icahn 337,474,287 2,067,297 8,383,437 Sarah B. Kavanagh 337,602,211 1,939,373
Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, April 29, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53393 Participant Event Dial-in: +1 (888) 506-
Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026 Time: 8:00 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392 Pa
SC 13G - Bausch & Lomb Corp (0001860742) (Subject)